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Unproven value of end-of-treatment and serial 
follow-up FDG-PET in primary mediastinal B-cell 
lymphoma 
A recent study by Melani et al.1 aimed to determine the
value of end-of-treatment FDG-PET and serial follow-up
FDG-PET in patients with primary mediastinal B-cell
lymphoma (PMBCL) treated with dose-adjusted EPOCH-
R. End-of-treatment FDG-PET was performed in 80
patients, 57 of whom received 144 serial follow-up 
FDG-PET scans. End-of-treatment FDG-PET scans were
interpreted according to the Deauville criteria, with a
score of 4 or 5 considered to indicate a positive result.
After treatment, 55/80 (69%) patients had negative end-
of-treatment FDG-PET results. With a median follow up
of 8.4 years (range 1.8-18.4 years), only 1 relapse (1.8%)
occurred in these 55 patients, therefore yielding a nega-
tive predictive value (NPV) of 98.2% for end-of-treat-
ment FDG-PET. On the other hand, end-of-treatment
FDG-PET was positive in 25 patients. Despite the very
long follow-up period, only 5/25 (20%) with positive
end-of-treatment FDG-PET results appeared to suffer
from treatment failure. Of the 6 patients with treatment
failure (one with negative and five with positive end-of-
treatment FDG-PET), 4 underwent biopsies that con-
firmed the presence of residual lymphoma, whilst treat-
ment failure was determined on the basis of serial follow-
up imaging in 2 patients. One patient without biopsy
confirmation showed progression on CT with an end-of-
treatment maximum standard uptake value (SUVmax) of
14.5, and received salvage radiotherapy. The second
patient without biopsy confirmation showed progression
on treatment with increases in SUVmax from 10.2 to 21.3
and appearance of new lesions, and received radiothera-
py. Four treatment failures were successfully salvaged
with radiotherapy alone (n=2), resection alone (n=1), and
chemotherapy/transplantation/radiotherapy (n=1). The
other 2 patients with treatment failure died after unsuc-
cessful administration of multiple salvage regimens. The
investigators observed a decrease in SUVmax on serial fol-
low-up FDG-PET scans in patients without disease
relapse, compared to an increase in SUVmax in patients
with treatment failure, and reported this to be a signifi-
cant predictor of outcome in the regression analysis.
Melani et al.1 postulated a negative end-of-treatment
FDG-PET result to be highly predictive of cure, whilst a
single positive end-of-treatment FDG-PET scan does not
accurately indicate treatment failure. In addition, they
claimed that serial follow-up FDG-PET imaging effective-
ly discriminates residual disease from post-treatment
inflammatory changes, which may help to identify
patients who require additional radiotherapy.
However, we disagree with their conclusions.
Considering their claim that end-of-treatment FDG-PET
has a high NPV for ruling out residual lymphoma, we
believe that the low number of treatment failures in
end-of-treatment FDG-PET negative patients may more
likely be a reflection of the low incidence of disease
relapse (6/80, 7.5%) rather than the discriminatory
value of end-of-treatment FDG-PET. Even a diagnostic
test without any discriminatory value at all (i.e., a test
which would classify all patients as negative) would
have a high NPV of 92.5% (74/80) in that scenario.
Thus, FDG-PET had only minor additional value in that
context. Note that the relapse rates were higher in other
comparable studies, with relapse rates up to 9.4% in
PMBCL patients with negative end-of-treatment FDG-
PET results after immunochemotherapy who did not
receive radiotherapy.2-4 Of note, in diffuse large B-cell
lymphoma (DLBCL), which has a considerably higher
incidence of disease relapse than PMBCL, the NPV of
end-of-treatment FDG-PET decreases enormously.5-7
One study even reported that patients with high-risk
DLBCL (as determined by the National Comprehensive
Cancer Network International Prognostic index
(NCCN-IPI) had a dismal progression-free survival of
only 38.5% despite a negative end-of-treatment FDG-
PET result.7
Furthermore, for several reasons we do not agree with
Melani et al.1 when they state that serial follow-up FDG-
PET has value in discriminating patients with residual
disease from those with therapeutic inflammation in
order to decide which patients need additional radiother-
apy. Firstly, we believe that as a result of the very low
number of patients experiencing treatment failure (n=6)
in their cohort, no clear conclusion can be drawn as to
the value of serial follow-up FDG-PET in predicting treat-
ment failure. Secondly, it should be mentioned that the
study by Melani et al.1 suffered from incorporation bias.
Note that the value of the index test (serial follow-up
FDG-PET) was determined using serial follow-up FDG-
PET findings as reference standard in 2/6 cases of (pre-
sumed) treatment failure which were not confirmed by
biopsy. Thirdly, of the 5 patients with treatment failure
and positive end-of-treatment FDG-PET results, only 3
(60%) were successfully salvaged (2 with radiotherapy,
and 1 with resection), whilst 2 died despite the applica-
tion of multiple salvage regimens, indicating that (early)
detection of treatment failure using multiple FDG-PET
scans had no value in these patients in terms of a survival
benefit. Of the 2 patients successfully treated with radio-
therapy, it remains unknown whether the radiotherapy
was actually successful in eradicating the lymphoma as
histological evidence of residual disease was lacking and
disease presence was only determined by means of serial
follow-up FDG-PET findings. Note that multiple studies
have shown that the application of routine follow-up
FDG-PET examinations has no survival benefit in
patients with negative end-of-treatment FDG-PET
results.8-10 Considering the very low incidence of treat-
ment failure in PMBCL patients with positive end-of-
treatment FDG-PET results, the lack of a survival benefit
of routine follow-up imaging studies may also apply to
this group of patients. 
In conclusion, the high NPV of end-of-treatment FDG-
PET in PMBCL remains unproven because the favorable
prognosis of patients with negative end-of-treatment
FDG-PET results may be a reflection of the generally
good prognosis of patients with PMBCL rather than the
value of end-of-treatment FDG-PET in ruling out residual
lymphoma. Multiple studies in DLBCL have already
revealed that end-of-treatment FDG-PET is unable to
exclude residual lymphoma, with high proportions of
patients developing disease relapse during follow up.5
Finally, we believe that the value of serial follow-up FDG-
PET in determining residual lymphoma remains
unproven: the number of patients who experienced treat-
ment failure was very low; the reference standard was
inadequate and included serial follow-up FDG-PET find-
ings resulting in incorporation bias; and there was a lack
of proof that serial follow-up FDG-PET improves patient
survival.
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